Aligos Therapeutics (NASDAQ:ALGS) vs. Kiromic BioPharma (NASDAQ:KRBP) Head to Head Analysis

Aligos Therapeutics (NASDAQ:ALGS) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Profitability

This table compares Aligos Therapeutics and Kiromic BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,283.19%	-114.34%	-64.58%
Kiromic BioPharma	N/A	N/A	-277.46%

Valuation & Earnings

This table compares Aligos Therapeutics and Kiromic BioPharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$6.00 million	8.62	-$87.68 million	($13.32)	-1.08
Kiromic BioPharma	N/A	N/A	-$26.90 million	($3.50)	-0.43

Kiromic BioPharma has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are owned by institutional investors. 8.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 20.6% of Kiromic BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Aligos Therapeutics has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Aligos Therapeutics and Kiromic BioPharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	0	0	1	0	3.00
Kiromic BioPharma	0	0	0	0	0.00

Aligos Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 420.83%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Aligos Therapeutics is more favorable than Kiromic BioPharma.

Summary

Aligos Therapeutics beats Kiromic BioPharma on 7 of the 13 factors compared between the two stocks.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Kiromic BioPharma

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.